Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common diabetes drug unlock the mystery of insulin failure?

NCT ID NCT06830096

Recruiting now Knowledge-focused Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This study investigates whether a key channel in insulin-producing cells becomes less active as type 2 diabetes progresses. Researchers will give a single 10 mg dose of glipizide, a drug that blocks this channel, to people with and without type 2 diabetes and measure their insulin responses over 90 minutes. The goal is to understand if reduced channel activity contributes to the poor blood sugar control seen in type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
glipizide
What this could lead to
If successful, this could reveal a new mechanism behind insulin secretion failure in type 2 diabetes, potentially guiding future treatments.
What could go wrong
This is a small, early-stage study with only 40 participants, so results may not apply broadly. Glipizide can cause low blood sugar, and the findings may not directly translate to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMPAIRED FASTING GLUCOSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY AND TYPE 2 DIABETES

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Washington University in St. Louis

    RECRUITING

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.